Scarica l'app Stockscreener
16.73
2.14%
0.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Short Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2% - MarketBeat
MLTX Price Today: MoonLake Immunotherapeutics Stock Price, Quote & Chart | MEXC - MEXC Exchange
MoonLake plunges after mixed results from skin disease trial - MSN
MoonLake Immunotherapeutics (MLTX) Proxy Filing Summary - Quartr
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Moonlake surges as no additional studies are required for lead drug - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? - MSN
Understanding the Setup: (MLTX) and Scalable Risk - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ: MLTX) puts 6.2% equity plan dilution to shareholder vote - Stock Titan
MoonLake Immunotherapeutics (MLTX) Proxy filing Summary - Quartr
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - AOL.com
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - The Motley Fool
Have Insiders Sold MoonLake Immunotherapeutics Shares Recently? - Sahm
Insider Sell: Matthias Bodenstedt Sells Shares of MoonLake Immun - GuruFocus
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - AOL.com
MoonLake (MLTX) CFO sells 2,426 shares under Rule 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Moonlake stock rating on HS potential By Investing.com - Investing.com Australia
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on HS potential - Investing.com
Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention - TipRanks
Insider Sell: CEO Santos da Silva Jorge Sells 150,000 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 Shares - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 Shares - MarketBeat
MoonLake Immunotherapeutics Chief Executive Officer Sold Shares Worth Over $2.7M - TradingView — Track All Markets
MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares - Stock Titan
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics - TipRanks
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
The Technical Signals Behind (MLTX) That Institutions Follow - Stock Traders Daily
Pre-planned MoonLake (NASDAQ: MLTX) CFO share sale totals 87,795 - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6%Here's Why - MarketBeat
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):